Deakin University
Browse

Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer in Australia

Version 2 2024-06-06, 10:34
Version 1 2020-11-10, 08:15
journal contribution
posted on 2024-06-06, 10:34 authored by T Khoo, Lan GaoLan Gao
Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer in Australia

History

Journal

Expert Review of Pharmacoeconomics and Outcomes Research

Volume

21

Pagination

415-423

Location

England

ISSN

1473-7167

eISSN

1744-8379

Language

English

Publication classification

C1 Refereed article in a scholarly journal

Issue

3

Publisher

TAYLOR & FRANCIS LTD